Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Edin Basic"'
Publikováno v:
European Journal of Haematology
Objectives Emerging treatments for relapsed or refractory multiple myeloma (rrMM) have led to increasing options for many patients. This study aimed to assess changes in utilization of these options in Germany with a focus on modern triplet regimens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ccbc845076d9aeb9ca7138794ce5d5c
http://europepmc.org/articles/PMC7894176
http://europepmc.org/articles/PMC7894176
Publikováno v:
Thrombosis and Haemostasis. 119:882-893
Background This study assessed changes in anticoagulation therapy over time in patients with atrial fibrillation (AF). Methods Analyses were performed on a claims-based dataset of 4 million health-insured individuals. The study population consisted o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0e277cf796c48a52a55c3c14550fdfd
https://doi.org/10.1055/s-0039-1683428
https://doi.org/10.1055/s-0039-1683428
Publikováno v:
Clinical Research in Cardiology. 108:1042-1052
Underuse of oral anticoagulation (OAC) for stroke prevention in atrial fibrillation (AF) results in thousands of preventable strokes in Germany each year. This study aimed to assess changes in antithrombotic therapy in AF patients after increased use
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe77879924808b4c20ba01686b1f060f
https://doi.org/10.1007/s00392-019-01437-7
https://doi.org/10.1007/s00392-019-01437-7
Autor:
Christian Morath, Jan Goßmann, Katharina Heller, Frank Eitner, Jan Steffen Jürgensen, Edin Basic, Klemens Budde, Michael Fischereder, Udo Riester, Nils Heyne, Wolfgang Arns, Fritz Diekmann, Marcel Naik, Wilfried Gwinner
Publikováno v:
Transplantation proceedings 52(10), 3103-3111 (2020). doi:10.1016/j.transproceed.2020.02.159
Transplantation proceedings 52(10), 3103-3111 (2020). doi:10.1016/j.transproceed.2020.02.159
Published by Elsevier Science, Amsterdam [u.a.]
Published by Elsevier Science, Amsterdam [u.a.]
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77f198f2a2c9100cac92459e27747ac2
Publikováno v:
Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen. 139:46-52
Zusammenfassung Hintergrund Venose Thromboembolien (VTE) manifestieren sich hauptsachlich in der tiefen Venenthrombose (TVT) oder der Lungenembolie (LE) und stellen weltweit die dritthaufigste kardiovaskulare Erkrankung dar. Belastbare Daten zur VTE-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5df2a3dacfe7f003ede87af1bdbc3076
https://doi.org/10.1016/j.zefq.2018.11.005
https://doi.org/10.1016/j.zefq.2018.11.005
Publikováno v:
Thrombosis and Haemostasis. 118:526-538
All pivotal trials have evaluated non–vitamin K oral antagonists (NOACs) against warfarin. However, in some regions of the world, phenprocoumon is the most widely used vitamin K antagonist (VKA). There is little evidence documenting effectiveness a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16d52a86a6f82f4d701f86f85e94eb44
https://doi.org/10.1160/th17-10-0733
https://doi.org/10.1160/th17-10-0733
Publikováno v:
The European Journal of Health Economics
Background In Germany, several triplet therapies for treating relapsed or refractory multiple myeloma (rrMM) patients have recently been approved. While most of them are administered intravenously, ixazomib-based combination is the only orally bioava
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40d15697d0a457dfc44dca1e6c664af7
https://pubmed.ncbi.nlm.nih.gov/32654072
https://pubmed.ncbi.nlm.nih.gov/32654072
Autor:
Ahmed H Seddik, Edin Basic, Eva Hradetzky, Dennis A Ostwald, Sebastian Himmler, Malina Müller
Publikováno v:
Expert review of pharmacoeconomicsoutcomes research. 19(2)
Patients with non-valvular atrial fibrillation (NVAF) have a five times higher stroke risk. For more than 50 years, vitamin K antagonists (VKAs) have been the primary medication for stroke prevention. Apixaban, a non-vitamin K oral anticoagulant (NOA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b92471fef53b30c35257204dfdc03fd4
https://pubmed.ncbi.nlm.nih.gov/30295561
https://pubmed.ncbi.nlm.nih.gov/30295561
Publikováno v:
European Heart Journal. 39
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::03edf15b69139fe7f8315705f3500943
https://doi.org/10.1093/eurheartj/ehy563.p3852
https://doi.org/10.1093/eurheartj/ehy563.p3852
Publikováno v:
Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen. 139
Venous thromboembolism (VTE) mainly manifests as deep vein thrombosis (TVT) or pulmonary embolism (LE), and is the third most common cardiovascular disease worldwide. However, robust evidence on the incidence of VTE in Germany is lacking.Estimation a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::670a59929373b80630c584c654add804
https://pubmed.ncbi.nlm.nih.gov/30477975
https://pubmed.ncbi.nlm.nih.gov/30477975